Mark Gudesblatt

3.1k total citations
61 papers, 959 citations indexed

About

Mark Gudesblatt is a scholar working on Pathology and Forensic Medicine, Neurology and Neurology. According to data from OpenAlex, Mark Gudesblatt has authored 61 papers receiving a total of 959 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pathology and Forensic Medicine, 15 papers in Neurology and 9 papers in Neurology. Recurrent topics in Mark Gudesblatt's work include Multiple Sclerosis Research Studies (36 papers), Botulinum Toxin and Related Neurological Disorders (5 papers) and Polyomavirus and related diseases (5 papers). Mark Gudesblatt is often cited by papers focused on Multiple Sclerosis Research Studies (36 papers), Botulinum Toxin and Related Neurological Disorders (5 papers) and Polyomavirus and related diseases (5 papers). Mark Gudesblatt collaborates with scholars based in United States, Israel and Canada. Mark Gudesblatt's co-authors include Jeffrey Wilken, Vijay Dhawan, David Eidelberg, Thomas Eckert, Steven J. Frucht, Andrew Feigin, Jean‐Paul Vonsattel, Stanley Fahn, Kathleen L. Poston and Chris C. Tang and has published in prestigious journals such as Neurology, The Lancet Neurology and Experimental Brain Research.

In The Last Decade

Mark Gudesblatt

55 papers receiving 936 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Gudesblatt United States	16	459	440	145	129	116	61	959
Emanuela Onesti Italy	20	372 0.8×	457 1.0×	130 0.9×	155 1.2×	267 2.3×	40	1.2k
A. Ali Chérif France	10	403 0.9×	594 1.4×	107 0.7×	97 0.8×	134 1.2×	22	1.0k
Nadir Abdelrahman United States	14	814 1.8×	233 0.5×	105 0.7×	74 0.6×	126 1.1×	30	1.1k
Meltem Demirkıran Türkiye	13	307 0.7×	418 0.9×	204 1.4×	281 2.2×	51 0.4×	35	1.0k
Daniela Pinter Austria	19	303 0.7×	328 0.7×	64 0.4×	167 1.3×	217 1.9×	62	1.1k
Thomas J. Lovely United States	17	354 0.8×	329 0.7×	168 1.2×	90 0.7×	114 1.0×	31	794
Teresa Costabile Italy	16	447 1.0×	186 0.4×	80 0.6×	53 0.4×	85 0.7×	34	709
Ester Reggio Italy	15	250 0.5×	236 0.5×	78 0.5×	147 1.1×	107 0.9×	22	654
Valerio Pisani Italy	14	162 0.4×	271 0.6×	247 1.7×	76 0.6×	135 1.2×	35	749
Johanna Krüger Finland	12	213 0.5×	190 0.4×	76 0.5×	122 0.9×	64 0.6×	48	664

Countries citing papers authored by Mark Gudesblatt

Since Specialization

Citations

This map shows the geographic impact of Mark Gudesblatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Gudesblatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Gudesblatt more than expected).

Fields of papers citing papers by Mark Gudesblatt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Gudesblatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Gudesblatt. The network helps show where Mark Gudesblatt may publish in the future.

Co-authorship network of co-authors of Mark Gudesblatt

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Gudesblatt. A scholar is included among the top collaborators of Mark Gudesblatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Gudesblatt. Mark Gudesblatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Golan, Daniel, et al.. (2024). Polysomnography parameters in a large cohort of people with multiple sclerosis. Sleep Medicine. 121. 236–240. 2 indexed citations

Cobb, Bryan, Richard J. Karpowicz, David Jones, et al.. (2024). Clinical Applications of Digital Biomarkers in Multiple Sclerosis: A Systematic Literature Review (P5-6.013). Neurology. 102(7_supplement_1).

Singer, B., Sibyl Wray, Mark Gudesblatt, et al.. (2024). Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study. Neurology and Therapy. 13(4). 1273–1285. 2 indexed citations

Attarian, Hrayr, Marijean Buhse, Daniel Golan, et al.. (2023). Multiple Sclerosis, Fatigue, Expanded Disability Status Scale: A Cross-Sectional Exploration of Sleep Efficiency and Quantitative Sleep Parameters. International Journal of MS Care. 26(2). 57–60. 3 indexed citations

Bogaardt, Hans, Daniel Golan, Stacie Attrill, et al.. (2023). Cognitive impairment, fatigue and depression in multiple sclerosis: Is there a difference between benign and non-benign MS?. Multiple Sclerosis and Related Disorders. 73. 104630–104630. 10 indexed citations

Gudesblatt, Mark, et al.. (2023). Dementia associated disorders, cognitive impairment and impact on social roles activities and participation: Patient centric impact. Alzheimer s & Dementia. 19(S5).

Covey, Thomas J., Daniel Golan, Robert C. Sergott, et al.. (2023). Peering further into the mind’s eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis. Journal of Neurology. 271(2). 658–673. 1 indexed citations

Cutter, Gary, Daniel Golan, Glen M. Doniger, et al.. (2022). Measuring cognitive function by the SDMT across functional domains: Useful but not sufficient. Multiple Sclerosis and Related Disorders. 60. 103704–103704. 12 indexed citations

Covey, Thomas J., Daniel Golan, Glen M. Doniger, et al.. (2022). Longitudinal assessment of the relationship between visual evoked potentials and cognitive performance in multiple sclerosis. Clinical Neurophysiology. 137. 66–74. 5 indexed citations

10.

Wilken, Jeffrey, Marijean Buhse, Iris‐Katharina Penner, et al.. (2022). Cognitive impairment in people with multiple sclerosis: Perception vs. performance – factors that drive perception of impairment differ for patients and clinicians. Multiple Sclerosis and Related Disorders. 69. 104410–104410. 7 indexed citations

11.

Covey, Thomas J., Daniel Golan, Glen M. Doniger, et al.. (2021). The relationship between cognitive impairment, cognitive fatigue, and visual evoked potential latency in people with multiple sclerosis. Multiple Sclerosis and Related Disorders. 57. 103349–103349. 7 indexed citations

12.

Gudesblatt, Mark, et al.. (2020). An Investigation of Headaches in Hypermobile Ehlers- Danlos Syndrome. 3(3). 1 indexed citations

13.

Cohen, Jeffrey A., Samuel F. Hunter, Theodore R. Brown, et al.. (2018). Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. Multiple Sclerosis Journal. 25(4). 601–609. 8 indexed citations

14.

Golan, Daniel, Mark Gudesblatt, Lori Fafard, et al.. (2018). Baseline cognitive function of patients with relapsing remitting multiple sclerosis is associated with therapeutic response to Natalizumab (P6.348). Neurology. 90(15_supplement). 1 indexed citations

15.

Gudesblatt, Mark, Lori Fafard, Jeffrey Wilken, et al.. (2018). Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis. CNS Drugs. 32(12). 1173–1181. 15 indexed citations

16.

Buckle, Guy J., Daniel S. Bandari, Jeffrey I. Greenstein, et al.. (2017). Characterization of Baseline Lymphocytes and Their Influence on Subsequent ALC and Lymphocyte Subset Decline in Patients with Relapsing Multiple Sclerosis Treated with Delayed-release Dimethyl Fumarate in a Retrospective, Multicenter, Observational Study (REALIZE) (P5.376). Neurology. 88(16_supplement). 1 indexed citations

17.

Cascione, Mark, Mark S. Freedman, Mark Agius, et al.. (2014). First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 3(5). 620–628. 13 indexed citations

18.

Singer, B., Mark Gudesblatt, Neetu Agashivala, et al.. (2014). Patient-Reported Outcomes After Therapy Switch to Fingolimod: Post-hoc Subgroup Analysis of the EPOC Study (P3.183). Neurology. 82(10_supplement). 1 indexed citations

19.

Wilken, Jeffrey, Robert L Kane, Mark Gudesblatt, et al.. (2013). Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab. International Journal of MS Care. 15(3). 120–128. 33 indexed citations

20.

Mammis, Antonios, Mark Gudesblatt, & Alon Y. Mogilner. (2011). Peripheral Neurostimulation for the Treatment of Refractory Cluster Headache, Long-Term Follow-Up: Case Report. Neuromodulation Technology at the Neural Interface. 14(5). 432–435. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact